Impact of empagliflozin on diabetic kidney disease

Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule‐glomerular feedback, thereby protect against diabetes‐induced caidio‐renal injuries.[Image: see text]

Detalles Bibliográficos
Autor principal: Koya, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583951/
https://www.ncbi.nlm.nih.gov/pubmed/28035769
http://dx.doi.org/10.1111/jdi.12615
_version_ 1783261377681424384
author Koya, Daisuke
author_facet Koya, Daisuke
author_sort Koya, Daisuke
collection PubMed
description Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule‐glomerular feedback, thereby protect against diabetes‐induced caidio‐renal injuries.[Image: see text]
format Online
Article
Text
id pubmed-5583951
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55839512017-09-06 Impact of empagliflozin on diabetic kidney disease Koya, Daisuke J Diabetes Investig Commentaries Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule‐glomerular feedback, thereby protect against diabetes‐induced caidio‐renal injuries.[Image: see text] John Wiley and Sons Inc. 2017-02-22 2017-09 /pmc/articles/PMC5583951/ /pubmed/28035769 http://dx.doi.org/10.1111/jdi.12615 Text en © 2016 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Commentaries
Koya, Daisuke
Impact of empagliflozin on diabetic kidney disease
title Impact of empagliflozin on diabetic kidney disease
title_full Impact of empagliflozin on diabetic kidney disease
title_fullStr Impact of empagliflozin on diabetic kidney disease
title_full_unstemmed Impact of empagliflozin on diabetic kidney disease
title_short Impact of empagliflozin on diabetic kidney disease
title_sort impact of empagliflozin on diabetic kidney disease
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583951/
https://www.ncbi.nlm.nih.gov/pubmed/28035769
http://dx.doi.org/10.1111/jdi.12615
work_keys_str_mv AT koyadaisuke impactofempagliflozinondiabetickidneydisease

Ejemplares similares